Human ST6 Gal Sialyltransferase 1/
ST6GAL1 Antibody
Human ST6 Gal Sialyltransferase 1/
ST6GAL1 Antibody Summary
Lys27-Cys406
Accession # P15907
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1 by Western Blot. Western blot shows lysates of Daudi human Burkitt's lymphoma cell line. PVDF Membrane was probed with 1 µg/mL of Goat Anti-Human ST6 Gal Sialyltransferase 1/ST6GAL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5924) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF019). A specific band was detected for ST6GAL1 at approximately 56 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.
View Larger
ST6 Gal Sialyltransferase 1/ST6GAL1 in Human Liver. ST6 Gal Sialyltransferase 1/ST6GAL1 was detected in immersion fixed paraffin-embedded sections of human liver using Goat Anti-Human ST6 Gal Sialyltransferase 1/ST6GAL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5924) at 0.3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in hepatocytes. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.
View Larger
ST6 Gal Sialyltransferase 1/ST6GAL1 in Human Prostate. ST6 Gal Sialyltransferase 1/ST6GAL1 was detected in immersion fixed paraffin-embedded sections of human prostate using Goat Anti-Human ST6 Gal Sialyltransferase 1/ST6GAL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5924) at 1 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in glandular epithelial cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1 by Simple WesternTM. Simple Western lane view shows lysates of Daudi human Burkitt's lymphoma cell line, loaded at 0.2 mg/mL. A specific band was detected for ST6 Gal Sialyltransferase 1/ST6GAL1 at approximately 64 kDa (as indicated) using 10 µg/mL of Goat Anti-Human ST6 Gal Sialyltransferase 1/ST6GAL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5924) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.
View Larger
Detection of ST6 Gal Sialyltransferase 1/ST6GAL1 in U266 human myeloma cell line (Positive) & RT‑4 human urinary bladder transitional cell papilloma cell line (Negative). ST6 Gal Sialyltransferase 1/ST6GAL1 was detected in immersion fixed U266 human myeloma cell line (Positive) & RT‑4 human urinary bladder transitional cell papilloma cell line (Negative) using Goat Anti-Human ST6 Gal Sialyltransferase 1/ST6GAL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5924) at 5 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to Golgi. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Western Blot ST6Gal-I expression in OV4 ovarian cancer cells. OV4 cells that have no endogenous ST6Gal-I were stably transduced with either empty vector or ST6Gal-I-expressing lentivirus. ST6Gal-I expression was confirmed by immunocytochemistry (A) and immunoblotting (B). ST6Gal-I localization to the Golgi is shown by co-localization with the Golgi marker GM-130 in the ST6Gal-I forced expression line (C) Par = parental; EV = empty vector; ST6 = cells with forced ST6Gal-I expression. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Immunocytochemistry/Immunofluorescence ST6Gal-I expression in OV4 ovarian cancer cells. OV4 cells that have no endogenous ST6Gal-I were stably transduced with either empty vector or ST6Gal-I-expressing lentivirus. ST6Gal-I expression was confirmed by immunocytochemistry (A) and immunoblotting (B). ST6Gal-I localization to the Golgi is shown by co-localization with the Golgi marker GM-130 in the ST6Gal-I forced expression line (C) Par = parental; EV = empty vector; ST6 = cells with forced ST6Gal-I expression. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Western Blot Cells that are resistant to cisplatin have upregulated endogenous ST6Gal-I. (A) Pa-1 cells with ST6Gal-I knockdown (sh.ST6) were exposed to cisplatin for 3 weeks, and the remaining viable population (sh.ST6 cis-res) was expanded and immunoblotted for ST6Gal-I. (B) Pa-1 cells with ST6Gal-I knockdown do not upregulate ST6Gal-I expression following a 24-hr treatment with cisplatin (sh.ST6 + cis). (C) Parental A2780 ovarian cancer cells (Par) and a cisplatin-resistant derivative population (Cis-res) were immunoblotted for endogenous ST6Gal-I. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Western Blot Cells that are resistant to cisplatin have upregulated endogenous ST6Gal-I. (A) Pa-1 cells with ST6Gal-I knockdown (sh.ST6) were exposed to cisplatin for 3 weeks, and the remaining viable population (sh.ST6 cis-res) was expanded and immunoblotted for ST6Gal-I. (B) Pa-1 cells with ST6Gal-I knockdown do not upregulate ST6Gal-I expression following a 24-hr treatment with cisplatin (sh.ST6 + cis). (C) Parental A2780 ovarian cancer cells (Par) and a cisplatin-resistant derivative population (Cis-res) were immunoblotted for endogenous ST6Gal-I. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Western Blot Cells that are resistant to cisplatin have upregulated endogenous ST6Gal-I. (A) Pa-1 cells with ST6Gal-I knockdown (sh.ST6) were exposed to cisplatin for 3 weeks, and the remaining viable population (sh.ST6 cis-res) was expanded and immunoblotted for ST6Gal-I. (B) Pa-1 cells with ST6Gal-I knockdown do not upregulate ST6Gal-I expression following a 24-hr treatment with cisplatin (sh.ST6 + cis). (C) Parental A2780 ovarian cancer cells (Par) and a cisplatin-resistant derivative population (Cis-res) were immunoblotted for endogenous ST6Gal-I. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Immunocytochemistry/Immunofluorescence ST6Gal-I expression in OV4 ovarian cancer cells. OV4 cells that have no endogenous ST6Gal-I were stably transduced with either empty vector or ST6Gal-I-expressing lentivirus. ST6Gal-I expression was confirmed by immunocytochemistry (A) and immunoblotting (B). ST6Gal-I localization to the Golgi is shown by co-localization with the Golgi marker GM-130 in the ST6Gal-I forced expression line (C) Par = parental; EV = empty vector; ST6 = cells with forced ST6Gal-I expression. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Immunocytochemistry/Immunofluorescence ST6Gal-I knockdown in Pa-1 ovarian cancer cells. Pa-1 cells that have high endogenous ST6Gal-I were stably transduced with either empty vector lentivirus, or virus expressing shRNA for ST6Gal-I. ST6Gal-I knockdown was confirmed by immunocytochemistry (A) and immunoblotting (B). ST6Gal-I localization to the Golgi was confirmed by co-localization with the Golgi marker GM-130 in the empty vector transduced line (C) Par = parental; EV = empty vector; sh.ST6 = cells stably expressing shRNA for ST6Gal-I. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 by Western Blot ST6Gal-I knockdown in Pa-1 ovarian cancer cells. Pa-1 cells that have high endogenous ST6Gal-I were stably transduced with either empty vector lentivirus, or virus expressing shRNA for ST6Gal-I. ST6Gal-I knockdown was confirmed by immunocytochemistry (A) and immunoblotting (B). ST6Gal-I localization to the Golgi was confirmed by co-localization with the Golgi marker GM-130 in the empty vector transduced line (C) Par = parental; EV = empty vector; sh.ST6 = cells stably expressing shRNA for ST6Gal-I. Image collected and cropped by CiteAb from the following publication (https://ovarianresearch.biomedcentral.com/articles/10.1186/1757-2215-6-25), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human Human ST6 Gal Sialyltransferase 1/ ST6GAL1 Antibody by Western Blot Cells that are resistant to cisplatin have upregulated endogenous ST6Gal-I. (A) Pa-1 cells with ST6Gal-I knockdown (sh.ST6) were exposed to cisplatin for 3 weeks, and the remaining viable population (sh.ST6 cis-res) was expanded and immunoblotted for ST6Gal-I. (B) Pa-1 cells with ST6Gal-I knockdown do not upregulate ST6Gal-I expression following a 24-hr treatment with cisplatin (sh.ST6 + cis). (C) Parental A2780 ovarian cancer cells (Par) and a cisplatin-resistant derivative population (Cis-res) were immunoblotted for endogenous ST6Gal-I. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/23578204), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: ST6 Gal Sialyltransferase 1/ST6GAL1
Sialic acid molecules attached to glycoproteins or glycosphingolipids play important roles in various biological processes such as immune recognition, pathogen infection, and cell adhesion (1). Sialyltransferases are key enzymes that regulate the cellular levels of sialic acid-containing molecules. Beta-galactosamide alpha‑2,6‑sialyltransferase 1 encoded by the ST6GAL1 gene is a type-II membrane protein localized in the trans-Golgi network and catalyzes 2,6-sialylation of Gal beta 1,4‑GlcNAc structures on N-glycans (2). The enzyme is involved in the generation of the cell-surface carbohydrate determinants and differentiation antigens HB‑6, CD75, and CD76 (3). ST6GAL1 is highly expressed in the liver and also expressed in most other tissues to some extent (4). ST6GAL1 deficiency causes abnormalities in B-cell immunoreactivity (5). The expression and activity of ST6GAL1 are associated with tumor metastasis in breast (6) and colon (7) cancers. The majority of ST6GAL1 in the liver is cleaved and secreted into the serum (8) and may be used as a biomarker for hepatitis diseases (9).
- Varki, A. et al. (1999) Essentials of Glycobiology, Cold Spring Harbor Laboratory Press, pp195.
- Weinstein, J. et al. (1987) J. Biol. Chem. 262:17735.
- Bast, B.J. et al. (1992) J. Cell Biol. 116:423.
- Kitagawa, H. and J.C. Paulson (1994) J. Biol. Chem. 269:17872.
- Hennet, T. et al. (1998) Proc. Natl. Acad. Sci. USA 95:4504.
- Recchi, M.A. et al. (1998) Cancer Res. 58:4066.
- Dall’Olio, F. et al. (2001) Eur. J. Biochem. 268:5876.
- Weinstein, J. et al. (1987) J. Biol. Chem. 262:17735.
- Kitazume, S. et al. (2009) Glycobiology 19:479.
Product Datasheets
Citations for Human ST6 Gal Sialyltransferase 1/
ST6GAL1 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
30
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Genetic risk factors for COVID-19 and influenza are largely distinct
Authors: Kosmicki, JA;Marcketta, A;Sharma, D;Di Gioia, SA;Batista, S;Yang, XM;Tzoneva, G;Martinez, H;Sidore, C;Kessler, MD;Horowitz, JE;Roberts, GHL;Justice, AE;Banerjee, N;Coignet, MV;Leader, JB;Park, DS;Lanche, R;Maxwell, E;Knight, SC;Bai, X;Guturu, H;Baltzell, A;Girshick, AR;McCurdy, SR;Partha, R;Mansfield, AJ;Turissini, DA;Zhang, M;Mbatchou, J;Watanabe, K;Verma, A;Sirugo, G;Colorado Center for Precision Medicine, ;Mayo Clinic Project Generation, ;Regeneron Genetics Center, ;University of California Los Angeles ATLAS Collaboration, ;Ritchie, MD;Salerno, WJ;Shuldiner, AR;Rader, DJ;Mirshahi, T;Marchini, J;Overton, JD;Carey, DJ;Habegger, L;Reid, JG;Economides, A;Kyratsous, C;Karalis, K;Baum, A;Cantor, MN;Rand, KA;Hong, EL;Ball, CA;Siminovitch, K;Baras, A;Abecasis, GR;Ferreira, MAR;
Nature genetics
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Dynamic glycoprotein hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent circulating tumor cell clusters in breast cancer
Authors: Dashzeveg, NK;Jia, Y;Zhang, Y;Gerratana, L;Patel, P;Shajahan, A;Dandar, T;Ramos, EK;Almubarak, HF;Adorno-Cruz, V;Taftaf, R;Schuster, EJ;Scholten, D;Sokolowski, MT;Reduzzi, C;El-Shennawy, L;Hoffmann, AD;Manai, M;Zhang, Q;D'Amico, P;Azadi, P;Colley, KJ;Platanias, LC;Shah, AN;Gradishar, WJ;Cristofanilli, M;Muller, WA;Cobb, BA;Liu, H;
Cancer discovery
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
ST6GAL1 inhibits metastasis of hepatocellular carcinoma via modulating sialylation of MCAM on cell surface
Authors: X Zou, J Lu, Y Deng, Q Liu, X Yan, Y Cui, X Xiao, M Fang, F Yang, H Sawaki, T Sato, B Tan, X Lu, B Feng, A Kuno, H Narimatsu, C Gao, Y Zhang
Oncogene, 2022-12-17;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
Authors: J Van Coilli, T Pongracz, J Rahmöller, HJ Chen, CE Geyer, LA van Vught, JS Buhre, T Šušti?, TLJ van Osch, M Steenhuis, W Hoepel, W Wang, AS Lixenfeld, J Nouta, S Keijzer, F Linty, R Visser, MD Larsen, EL Martin, I Künsting, S Lehrian, V von Kopylo, C Kern, HB Lunding, M de Winther, N van Mourik, T Rispens, T Graf, MA Slim, RP Minnaar, MK Bomers, JJ Sikkens, APJ Vlaar, CE van der Sc, J den Dunnen, M Wuhrer, M Ehlers, G Vidarsson, Fatebenefr, UMC COVID-
EBioMedicine, 2022-12-16;87(0):104408.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Deficiency in ST6GAL1, one of the two alpha 2,6-sialyltransferases, has only a minor effect on the pathogenesis of prion disease
Authors: Natallia Makarava, Elizaveta Katorcha, Jennifer Chen-Yu Chang, Joseph T. Y. Lau, Ilia V. Baskakov
Frontiers in Molecular Biosciences
-
alpha2,6 Sialylation mediated by ST6GAL1 promotes glioblastoma growth
Authors: S Gc, K Tuy, L Rickenback, R Jones, A Chakrabort, CR Miller, EA Beierle, VS Hanumanthu, AN Tran, JA Mobley, SL Bellis, AB Hjelmeland
JCI Insight, 2022-11-08;7(21):.
Species: Human
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC, Western Blot -
Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness
Authors: NC Hait, A Maiti, R Wu, VL Andersen, CC Hsu, Y Wu, DG Chapla, K Takabe, ME Rusiniak, W Bshara, J Zhang, KW Moremen, JTY Lau
Cancer Gene Therapy, 2022-06-08;0(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Multi-Faceted Effects of ST6Gal1 Expression on Precursor B-Lineage Acute Lymphoblastic Leukemia
Authors: Mingfeng Zhang, Tong Qi, Lu Yang, Daniel Kolarich, Nora Heisterkamp
Frontiers in Oncology
-
Sialyltransferase ST6GAL-1 mediates resistance to chemoradiation in rectal cancer
Authors: M Smithson, R Irwin, G Williams, KL Alexander, LE Smythies, M Nearing, MC McLeod, S Al Diffalh, SL Bellis, KM Hardiman
The Journal of Biological Chemistry, 2022-01-15;0(0):101594.
Species: Human
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC, Western Blot -
Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells
Authors: CM Britain, N Bhalerao, AD Silva, A Chakrabort, DJ Buchsbaum, MR Crowley, DK Crossman, YJK Edwards, SL Bellis
J Biol Chem, 2020-11-23;0(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Regulation of inflammatory signaling by the ST6Gal-I sialyltransferase
Authors: AT Holdbrooks, KE Ankenbauer, J Hwang, SL Bellis
PLoS ONE, 2020-11-09;15(11):e0241850.
Species: Mouse
Sample Types: Cell Lysates
Applications: Western Blot -
Modulation of glycosyltransferase ST6Gal-I in gastric cancer-derived organoids disrupts homeostatic epithelial cell turnover
Authors: KL Alexander, CA Serrano, A Chakrabort, M Nearing, LN Council, A Riquelme, M Garrido, SL Bellis, LE Smythies, PD Smith
J. Biol. Chem., 2020-08-06;0(0):.
Species: Human
Sample Types: Organoid
Applications: ICC, IHC -
Sialylation of FGFR1 by ST6Gal?I overexpression contributes to ovarian cancer cell migration and chemoresistance
Authors: L Ou, X He, N Liu, Y Song, J Li, L Gao, X Huang, Z Deng, X Wang, S Lin
Mol Med Rep, 2020-01-20;21(3):1449-1460.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells
Authors: KA Dorsett, RB Jones, KE Ankenbauer, AB Hjelmeland, SL Bellis
J Ovarian Res, 2019-10-14;12(1):93.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Transfer of Functional Cargo in Exomeres
Authors: Q Zhang, JN Higginboth, DK Jeppesen, YP Yang, W Li, ET McKinley, R Graves-Dea, J Ping, CM Britain, KA Dorsett, CL Hartman, DA Ford, RM Allen, KC Vickers, Q Liu, JL Franklin, SL Bellis, RJ Coffey
Cell Rep, 2019-04-04;0(0):.
Species: Human
Sample Types: Exosomes
Applications: Western Blot -
Unravelling the Role of O-glycans in Influenza A Virus Infection
Authors: J Mayr, K Lau, JCC Lai, IA Gagarinov, Y Shi, S McAtamney, RWY Chan, J Nicholls, M von Itzste, T Haselhorst
Sci Rep, 2018-11-06;8(1):16382.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
Glycoengineering design options for IgG1 in CHO cells using precise gene editing
Authors: MA Schulz, W Tian, Y Mao, J Van Coilli, L Sun, JS Larsen, YH Chen, C Kristensen, SY Vakhrushev, H Clausen, Z Yang
Glycobiology, 2018-07-01;0(0):.
Species: Hamster
Sample Types: Whole Cells
Applications: ICC -
The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1? signaling
Authors: RB Jones, KA Dorsett, AB Hjelmeland, SL Bellis
J. Biol. Chem., 2018-02-23;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Western Blot -
Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
Authors: CM Britain, AT Holdbrooks, JC Anderson, CD Willey, SL Bellis
J Ovarian Res, 2018-02-05;11(1):12.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor
Authors: AT Holdbrooks, CM Britain, SL Bellis
J. Biol. Chem., 2017-12-12;0(0):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage
Authors: A Chakrabort, KA Dorsett, HQ Trummell, ES Yang, PG Oliver, JA Bonner, DJ Buchsbaum, SL Bellis
J. Biol. Chem., 2017-11-30;0(0):.
Species: Human
Sample Types: Recombinant Protein
Applications: Western Blot -
B-cell-independent sialylation of IgG
Authors: Mark B Jones
Proc Natl Acad Sci USA, 2016-06-14;113(26):7207-12.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC-Fr -
The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype
Cancer Res, 2016-05-23;0(0):.
Species: Human
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC-P, Western Blot -
Glycosyltransferase ST6GAL1 contributes to the regulation of pluripotency in human pluripotent stem cells
Authors: Yu-Chieh Wang, Jason W. Stein, Candace L. Lynch, Ha T. Tran, Chia-Yao Lee, Ronald Coleman et al.
Scientific Reports
-
Sialylation by beta -galactoside alpha -2,6-sialyltransferase and N-glycans regulate cell adhesion and invasion in human anaplastic large cell lymphoma
Authors: OSAMU SUZUKI, MASAFUMI ABE, YUKO HASHIMOTO
International Journal of Oncology
-
Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: regulatory roles of cell surface glycans.
Authors: Suzuki O, Abe M
Int J Oncol, 2014-03-04;44(5):1433-42.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
Treatment Response in Kawasaki Disease Is Associated with Sialylation Levels of Endogenous but Not Therapeutic Intravenous Immunoglobulin G
Authors: Shohei Ogata, Chisato Shimizu, Alessandra Franco, Ranim Touma, John T. Kanegaye, Biswa P. Choudhury et al.
PLoS ONE
-
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells.
Authors: Schultz, Matthew, Swindall, Amanda F, Wright, John W, Sztul, Elizabet, Landen, Charles, Bellis, Susan L
J Ovarian Res, 2013-04-11;6(1):25.
Species: Human
Sample Types: Cell Lysates, Whole Cells
Applications: ICC, Western Blot -
ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.
Authors: Swindall A, Londono-Joshi A, Schultz M, Fineberg N, Buchsbaum D, Bellis S
Cancer Res, 2013-01-28;73(7):2368-78.
Species: Human
Sample Types: Whole Cells, Whole Tissue
Applications: IHC, Western Blot -
Sialylation of MUC4b N-glycans by ST6GAL1 orchestrates human airway epithelial cell differentiation associated with Type-2 inflammation
Authors: Zhou X, Kinlough CL, Hughey RP et al.
JCI Insight
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human ST6 Gal Sialyltransferase 1/
ST6GAL1 Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human ST6 Gal Sialyltransferase 1/
ST6GAL1 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Used this Ab for both Western and immunofluorescence on mouse ST6GAL1 transfected CHO cells. Fixed cells with 4% Paraformaldehyde and permeabilized with 0.5% saponin.
